Chemistry, Manufacturing and Controls (CMC):
- Expanded selection and assessment of potential CMO(s) for
process and analytical development with Phase I manufacture.
There are a limited number of CMO’s who are:
• licensed for controlled substance / cannabinoid use and
manufacture, AND
• able to manufacture a sterile topical formulation under GMP
for human use
- CMO(s) selection to support Phase I development and
manufacture will be complete in early Q1/2019.
--------------------------------------------------------------------------------------------------------
They talking to big biotech companies to partner on INM-085: Glaucoma 6 Billion dollar market....
Dual Mechanism of Action
Reduces the intraocular
pressure (IOP) in the
affected eyes
?Provide neuroprotection
for the retinal ganglion
cells (RGCs) and other
optic nerve tissues in the
affected eyes
Proprietary Delivery System
INM-085 utilizes a 1x per
day hydrogel to improve
compliance
?Preclinical animal data
showed enhanced
penetration of
cannabinoid molecules
through the cornea and
lens compared to control
INM-405: Orofacial Pain ManagementLocal (topical) administration for peripheral pain management
Temporomandibular Disorders (TMD)
• Musculoskeletal and Neuromuscular
• TMJ, muscles and tissues
• Mild to severe; 2x more women than men
• 5-12% of total population
• Treated with NSAIDS, anti-depressants
Trigeminal Neuralgia (TN)
• “The Suicide Pain”
• Severe, electric shock pain at root
• ~18,000 in USA (up to possibly 20K)
• Treated with surgical intervention, opioids,
anti-convulsants, BOTOXTM
--------------------------------------------------------------------------------------------------------
why Biosynthesis is a very big deal.
U N L O C K I N G C A N N A B I N O I D M E D I C I N E S
The cost of isolating sufficient quantities of
these cannabinoids in order to conduct
research is prohibitive.
The 90+ cannabinoids occur in extremely low
concentrations in the cannabis plant.
Despite the medical potential of these 90+ other cannabinoids, their
role in treating disease remains largely unexplored.
Explores the potential of all 90+ cannabinoid compounds,
NOT just THC & CBD
Selects specific cannabinoids (or combinations) that have
potential to play a role in regulating specific diseases
Biosynthesizes cannabinoids that are biologically identical
to those produced by the plant
Develops innovative, topically applied therapies for
diseases with high unmet medical needs
IMLFF
